Bayer's expanded therapies and strategic collaborations in India aim to drive pharmaceutical growth amidst regulatory challenges and pricing pressures.

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...

Zydus, a leading, discovery-based, global pharmaceutical company announced that the US FDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of ...

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value ...

Jan. 22, 2025 — A new national survey found that while many Americans use a device to monitor their heart, few share that data with their ... Study Shows Anti-Clotting Drug Reduced Bleeding ...

Our editors also may be in touch with follow-up questions. An elevated heart rate as a result of physical activity, such as going for a run, is common, but what should your heart rate look like at ...

Zydus Lifesciences has been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b trial testing its experimental oral treatment usnoflast in people with amyotrophic lateral ...

Zydus Lifesciences's Usnoflast receives Orphan Drug Designation from the USFDA for the treatment of Amyotrophic Lateral Sclerosis (ALS), a rare neurodegenerative disease. New Delhi, Jan 22 (PTI) Zydus ...

Zydus Lifesciences made headlines on Wednesday as the US health regulator bestowed Orphan Drug Designation upon Usnoflast, their developing treatment for amyotrophic lateral sclerosis (ALS). The US ...

“This Orphan Drug Designation from the USFDA underlines the urgent need to develop Usnoflast to address Amyotrophic Lateral Sclerosis (ALS), which is a fatal neurodegenerative disease," said Zydus' ...

Bino Pathiparampil, Head of Research, Elara Capital, says companies like Dr Reddy’s, Zydus, Cipla, Sun, can sustain a low-double digit EPS growth over the medium term. Low-double digit is 11%, 12%, 13 ...